91 results
Page 2 of 5
8-K
EX-99.1
7yqi9nudt 8ehbnh
15 May 23
Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
8:01am
PRE 14A
vrcy83 ptpmtm830g2
14 Apr 23
Preliminary proxy
4:05pm
8-K
EX-99.1
72ihgb3edzxbgazf09il
30 Mar 23
Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones
4:32pm
8-K
EX-99.1
5iqp2gw1bn9i8c1l
8 Nov 22
Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and Select Anticipated Milestones
4:31pm
S-8
EX-99.1
j4v76w26igp5cgxlpro
31 Aug 22
Registration of securities for employees
4:32pm
8-K
EX-99.1
nje19f
8 Aug 22
Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones
4:32pm
8-K
3yvs9ou1 man
26 Jul 22
Other Events
4:02pm
8-K
EX-99.1
dzntiarsb96unjgsycs
9 May 22
Sutro Biopharma Reports First Quarter 2022 Financial Results, Business Highlights, and Anticipated Milestones
4:31pm
POS AM
qdpcr
28 Feb 22
Prospectus update (post-effective amendment)
5:46pm
8-K
EX-99.1
60q67x79df
28 Feb 22
Sutro Biopharma Reports Full Year 2021 Financial Results, Business Highlights, and Anticipated 2022 Milestones
4:36pm
POSASR
mdv6a5 vt
28 Feb 22
Automatic shelf registration (post-effective amendment)
4:16pm
8-K
m6hrs4p
5 Jan 22
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
5:27pm
8-K
EX-99.1
3q7jx
5 Jan 22
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
5:27pm